肺栓塞致院外心脏骤停复苏期间溶栓可提高30天生存率:法国国家心脏骤停登记研究结果
该回顾性、观察性、多中心研究纳入2011年7月至2018年3月法国国家心脏骤停登记中所有成人院外心脏骤停、经移动ICU处置且入院时确诊肺栓塞的患者。共14253例入院患者中328例最终诊断为肺栓塞,246例纳入分析。复苏期间溶栓组58例(阿替普酶14例24%、替奈普酶43例74%、链激酶1例2%),30天生存率溶栓组高于对照组(16% vs 6%,P=.005,校正时序检验),但良好神经功能结局无显著差异(10% vs 5%,校正相对危险度1.97,95%CI 0.70-5.56)。ICU中位停留时间溶栓组1(0-5)天 vs 对照组1(0-3)天(P=.23)。
要点
- 肺栓塞致院外心脏骤停且复苏后恢复自主循环入院的患者,复苏期间溶栓组30天生存率16% vs 对照组6%(P=.005,校正时序检验)。
- 良好神经功能结局溶栓组10% vs 对照组5%,校正相对危险度1.97(95%CI 0.70-5.56),未达统计学显著。
- 溶栓组58例中阿替普酶14例(24%)、替奈普酶43例(74%)、链激酶1例(2%)。
- ICU中位停留时间溶栓组1(0-5)天 vs 对照组1(0-3)天(P=.23)。
- 该研究为回顾性、观察性、多中心研究,2011年7月至2018年3月法国国家心脏骤停登记数据。
适用人群与场景
- 成人院外心脏骤停患者,经移动ICU处置,入院时确诊肺栓塞,且入院时恢复自主循环。
处置流程与药物剂量
- 复苏期间溶栓组58例中,阿替普酶14例(24%)、替奈普酶43例(74%)、链激酶1例(2%);原文未写明各药剂量、给药途径、频次或疗程。
研究设计与关键结果
- 回顾性、观察性、多中心研究,2011年7月至2018年3月,共14253例入院患者中328例最终诊断肺栓塞,246例纳入分析。
- 复苏期间溶栓组58例,对照组为未溶栓患者;30天生存率溶栓组16% vs 对照组6%(P=.005,校正时序检验)。
- 良好神经功能结局溶栓组10% vs 对照组5%,校正相对危险度1.97(95%CI 0.70-5.56),未达统计学显著。
- ICU中位停留时间溶栓组1(0-5)天 vs 对照组1(0-3)天(P=.23)。
证据类型、等级与局限
- 证据类型:回顾性、观察性、多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于肺栓塞导致院外心脏骤停、经移动ICU处置且入院时恢复自主循环的成人患者,复苏期间溶栓与更高的30天生存率相关(16% vs 6%),但良好神经功能结局无显著差异(10% vs 5%,校正相对危险度1.97,95%CI 0.70-5.56)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pulmonary embolism (PE) represents 2% to 5% of all causes of out-of-hospital cardiac arrest (OHCA) and is associated with extremely unfavorable prognosis. In PE-related OHCA, inconsistent data showed that thrombolysis during cardiopulmonary resuscitation may favor survival.
METHODS: This was a retrospective, observational, multicenter study from July 2011 to March 2018. All adults with OHCA, treated by a mobile ICU and with a diagnosis of PE confirmed on hospital admission, were included. The primary end point was 30-day survival in a weighted population.
RESULTS: Of the 14,253 patients admitted to hospitals, 328 had a final diagnosis of PE and 246 were included in the analysis. In the group that received thrombolysis during resuscitation (n = 58), 14 (24%) received alteplase, 43 (74%) received tenecteplase, and one (2%) received streptokinase. Thirty-day survival was higher in the thrombolysis group than in the control group (16% vs 6%; P = .005; adjusted log-rank test) but the good neurologic outcome was not significantly different (10% vs 5%; adjusted relative risk, 1.97; 95% CI, 0.70-5.56). Median duration of stay in the ICU was 1 (0-5) day for the thrombolysis group and 1 (0-3) day for the control group (P = .23).
CONCLUSIONS: In patients with OHCA with confirmed PE and admitted with recuperation of spontaneous circulation in the hospital, there was significantly higher 30-day survival in those who received thrombolysis during cardiopulmonary resuscitation compared with patients who did not receive thrombolysis.
参考来源
- Javaudin F, Lascarrou JB, Le Bastard Q, et al. Thrombolysis During Resuscitation for Out-of-Hospital Cardiac Arrest Caused by Pulmonary Embolism Increases 30-Day Survival: Findings From the French National Cardiac Arrest Registry. Chest. 2019. PMID: 31381884. doi:10.1016/j.chest.2019.07.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。